Skincare brand Asaya has successfully raised ₹88 crore in a funding round at a post-money valuation of ₹400 crore, as reported by StartupFox. The round was led by RPSG Capital with participation from OTP Ventures, Huddle Ventures, Hyperscale Ventures and 72 Ventures. The funding round comprised both primary and secondary capital, with some early angel investors selling their stakes. This represents a significant valuation increase from the company's previous ₹138 crore post-money valuation achieved in September 2025, marking a near-tripling of valuation in under a year.
According to StartupFox, the fresh capital will be utilized for research and development, product expansion, distribution and hiring. Founded in 2021 by Neeraj Biyani, Eeti Sharma and Mandeep Singh Bhatia, Asaya sells skincare products targeting hyperpigmentation, dehydration and acne, with a portfolio spanning dark-spot correcting serums, even-tone creams, body sprays, cleansers and sunscreens. The company's competitive advantage centers on its proprietary, patented molecule called MelaMe, which the company claims is designed specifically for Indian skin types. CEO Neeraj Biyani, formerly a co-founder of beverage brand Paper Boat, leads the D2C-focused brand that sells through its own online channels, quick-commerce platforms and select offline retail outlets.
For the financial year ended March 2025, Asaya's operating entity, Wellspring Consumer Private Limited, reported revenue of ₹7.09 crore, as per its filings with the Registrar of Companies. The company has publicly targeted ₹35 crore in net revenue for the current fiscal year, representing significant growth potential. The valuation multiple of ₹400 crore against ₹7.09 crore in filed FY25 revenue reflects investor confidence in the brand's growth trajectory and the potential of its patented molecule, though it represents a wide filing-to-valuation gap that prices in future performance rather than current economics.
The funding comes amid heightened investor interest in India's beauty and personal care segment, particularly in brands offering ingredient-led and problem-specific products. Asaya's investment reflects a strategic shift where specialization beats breadth in Indian skincare, with investors paying premiums for depth in niche markets rather than broad market reach. The competitive field is crowded with brands like Foxtale, Deconstruct, Conscious Chemist and Pilgrim chasing overlapping D2C skincare demand, while larger houses like Dabur are entering the category through investments like RAS Luxury. The investment creates execution risks, as Asaya must continue compounding growth to justify its valuation before its next funding round, in a category where well-capitalized incumbents can copy positioning faster than patents can be replicated.
